Regeneron says its Covid-19 antibody cocktail helps prevent symptomatic Covid-19
April 12, 2021. Summarized by summa-bot.
Compression ratio: 43.8%. 2 min read.
Regeneron Pharmaceuticals Inc. signage is displayed outside their headquarters in Tarrytown, N.Y., U.S., on June 12, 2020. Regeneron Pharmaceuticals Inc. said it had begun human trials of a new antibody cocktail for Covid-19, part of an ambitious clinical-testing plan that could lead to a new treatment option by the end of summer if all goes well. Photographer: Michael Nagle/Bloomberg
New Phase 3 trial data finds a single shot of Regeneron's Covid-19 antibody cocktail was able to prevent symptomatic Covid-19 among people exposed to the virus, the company said Monday.
(CNN)New Phase 3 trial data finds a single shot of Regeneron's Covid-19 antibody cocktail was able to prevent symptomatic Covid-19 among people exposed to the virus, the company said Monday.
Regeneron said it will seek expansion of the emergency use authorization for the drug, which is currently available in the United States to treat mild-to-moderate Covid-19 in people already infected with the coronavirus.
In the new trial, the drug, named REGEN-COV, reduced risk of symptomatic infections by 81%, the company said Monday in a news release.
After 29 days, 11 people who received a single 1,200 mg dose of the treatment developed symptomatic Covid-19; 59 people who received a placebo developed symptomatic Covid-19.
Those who received the antibody cocktail and experienced a symptomatic infection resolved their symptoms in one week, the company said, compared to three weeks among those who received a placebo.
"Despite standard precautions to reduce transmission, nearly 10% of unvaccinated individuals living with an infected person developed symptomatic infections if they did not receive REGEN-COV," Dr. Myron Cohen, who leads the monoclonal antibody efforts for the COVID Prevention Network and is the director of the Institute for Global Health and Infectious Diseases at the University of North Carolina at Chapel Hill, said in a statement.
Adverse events occurred in 20% of patients who received the antibody drug and 29% of those who received a placebo, Regeneron said.
Regeneron said it will request an expansion of its US Food and Drug Administration emergency use authorization to include Covid-19 prevention and as a subcutaneous shot.
Eli Lilly and Company previously announced its monoclonal antibody therapy, bamlanivimab, helped prevent symptomatic Covid-19 infection among nursing home residents and staff.